Drug Profile


Alternative Names: Lonsurf; Orcantas; S 95005/TAS-102; T15, T20; T15/T20; TAS-102; TAS-102/S-95005; Tipiracil-hydrochloride/trifluridine; Trifluridine/tipiracil; Trifluridine/tipiracil hydrochloride

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer 3SBio; Boehringer Ingelheim; Servier; Taiho Pharmaceutical; University of Florida; University of Wisconsin-Madison
  • Class Antineoplastics; Nucleosides; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Thymidine phosphorylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer
  • Phase III Gastric cancer
  • Phase II Oesophageal cancer; Pancreatic cancer; Small cell lung cancer
  • Phase I Gastrointestinal cancer; Neuroendocrine tumours; Solid tumours

Most Recent Events

  • 01 Oct 2017 Phase-II clinical trials in Pancreatic cancer (Metastatic disease, Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (PO) (NCT02921737)
  • 08 Sep 2017 Updated efficacy and adverse events data from the phase I/II N-TASK FORCE trial in Colorectal cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 22 Aug 2017 Phase-I clinical trials in Neuroendocrine tumours (Metastatic disease, Combination therapy) in USA (PO) (NCT02943733)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top